• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibitionerefractory advanced cutaneous melanoma

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncPillai.pdf
    Size:
    79.18Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Pillai, Manon
    Hawkins, Robert E
    Jiang, Y.
    Lorigan, Paul C
    Thistlethwaite, Fiona C
    Thomas, M.
    Kirillova, N.
    Bridgeman, J. S.
    Kueberuwa, G.
    Guest, R. D.
    Roberts, Z. J.
    Show allShow less
    Affiliation
    The Christie, NHS Foundation Trust, Manchester, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background TIL products made from tumor digests showed a high overall response rate (ORR; 67%) and complete response (CR) rate (19%) and a safety profile consistent with lymphodepletion and high-dose interleukin (IL)-2 in a retrospective analysis of a single-center experience of TILs for compassionate use treatment of advanced cutaneous melanoma (n=21; Hawkins, et al. AACR 2021. ePoster LB150). This subanalysis assesses outcomes for pts who received TILs after prior checkpoint inhibition, a pt subset with limited treatment options. Methods Pts with metastatic cutaneous melanoma and no standard of care treatment options received lymphodepleting chemotherapy (cyclophosphamide �2 d; fludarabine �5 d) followed by TIL infusion and post-TIL high-dose IL-2. Safety was assessed by clinically significant adverse events (AEs). Efficacy assessments included ORR, CR rate, and overall survival (OS). Results Of 21 pts who underwent treatment between Oct 2011 and Aug 2019, 12 received prior PD-1 inhibitor (PD-1i) therapy and are reported herein. Median age was 55 y and 50% of pts were BRAF-mutated. Median no. of disease sites was 4, and 100% of pts had M1c or M1d disease (25% with M1d). All pts received prior CTLA-4i and all BRAF-mutated pts received prior BRAFi alone � MEKi. The most commonly reported AEs post-TIL infusion were thrombocytopenia (75%), pyrexia (50%), and rigors (50%). No treatment-related deaths occurred. With a median follow-up of 45.5 mo, the ORR was 58% and the CR rate was 8%. At data cutoff, 2 pts (17%) had durable ongoing responses (>30 mo post-TIL infusion). Median OS in this subanalysis and in the overall population was 21.3 mo. Conclusions In this subanalysis of pts with relapsed advanced melanoma after both PD-1i and CTLA-4i, and for some, BRAFi, outcomes of unselected autologous TILs were similar to those observed in all treated pts, with high response rates and a safety profile consistent with that of TIL therapy. Unselected TILs may address the unmet medical need for the poor-risk subset of pts with advanced melanoma who experience disease progression following checkpoint inhibition and, if applicable, targeted therapy.
    Citation
    Pillai M, Hawkins RE, Jiang Y, Lorigan PC, Thistlethwaite F, Thomas M, et al. 1058P Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition�refractory advanced cutaneous melanoma. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S882.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624716
    DOI
    10.1016/j.annonc.2021.08.1443
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.1443
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.1443
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.